Episode 45 · November 12, 2024 · 31m listen · 5,790 words · ~29 min read

Navigating the Regulatory Landscape of Medical Device Cybersecurity | Ep. 3 - Full Transcript | The Med Device Cyber Podcast

Read the complete, searchable transcript of Episode 45 of The Med Device Cyber Podcast - expert conversations on medical device cybersecurity, FDA premarket and postmarket guidance, SBOM management, threat modeling, and penetration testing.

Prefer the listening experience? Open the episode page for the synopsis, key takeaways, topics, and Apple / YouTube listen links.

Episode summary

In this episode of the Med Device Cyber Podcast, hosts Christian Espinosa, founder and CEO of Blue Goat Cyber, and his colleague Trevor delve into the critical and often overlooked aspects of cybersecurity within the medical device industry. They begin by categorizing medical device manufacturers into two primary groups: agile startups, often backed by venture capital, and large, established corporations. A central argument made is that many companies, particularly startups, frequently make the critical mistake of deferring cybersecurity considerations until the end of the product development lifecycle. This reactive approach, termed "bolting on security," occurs when teams scramble to meet regulatory requirements just before submitting their device for approval. The hosts contrast this inefficient method with the proactive "security by design" philosophy, which advocates for integrating security measures from the initial concept phase. They emphasize that neglecting security early on inevitably leads to significant delays, costly remediation, and potential rejection by regulatory bodies, posing a serious risk to product launch timelines and financial stability. The discussion then transitions to the complex regulatory landscape that governs medical devices, focusing primarily on the U.S. Food and Drug Administration (FDA) framework. The hosts demystify the FDA's risk-based classification system, which categorizes devices into Class 1 (low risk, e.g., bandages), Class 2 (moderate risk, e.g., powered wheelchairs), and Class 3 (high risk, e.g., implantable defibrillators). This classification directly determines the rigor of the required pre-market submission pathway, whether it's a 510(k) for devices similar to existing products, a De Novo for novel low-to-moderate risk devices, or the exhaustive Premarket Approval (PMA) for high-risk, life-sustaining devices. They stress that although FDA guidance is often phrased as a recommendation, it functions as a de facto requirement, and failing to adhere to its detailed documentation and security standards is a common reason for submission failures. To illustrate the tangible risks of inadequate security, the hosts provide a real-world example from their experience testing a Class 2 acne treatment laser. They explain the concept of "vulnerability chaining," where an attacker combines several minor flaws to achieve a major compromise. In this case, vulnerabilities included unprotected physical ports on a supposedly air-gapped device, kiosk software that could be crashed to access the underlying operating system, and applications running with excessive administrative privileges. By chaining these exploits, they gained full remote control, enabling them to alter the laser's intensity and disable its cooling mechanism—a dangerous modification that could cause severe burns to a patient. This powerful example underscores the necessity of a holistic security approach that addresses not only network and software vulnerabilities but also physical interfaces, ensuring patient safety and successful regulatory approval.

Key takeaways from this episode

Medical device manufacturers often fall into two categories: startups and large corporations, but both can make the mistake of treating cybersecurity as a last-minute compliance task.
Integrating cybersecurity from the beginning of the product design lifecycle ('security by design') is far more effective and less costly than 'bolting it on' just before regulatory submission.
The FDA classifies medical devices into Class 1 (low), 2 (medium), and 3 (high) based on patient risk, which dictates the stringency of the required pre-market submission process.
FDA guidance on cybersecurity should be treated as mandatory. Though often framed as recommendations, non-compliance is a leading cause of submission rejections.
'Vulnerability chaining' is a critical threat where attackers combine multiple low-severity weaknesses to achieve a high-impact compromise, such as taking full control of a device.
Even devices designed to be 'air-gapped' are not immune to threats; physical access to ports can bypass network security controls entirely.
The cybersecurity process for medical devices extends beyond the pre-market phase into post-market surveillance, requiring manufacturers to have a plan for monitoring and responding to new vulnerabilities.
Medical device cybersecurity requires a specialized skillset that goes beyond traditional IT penetration testing, involving hardware, embedded systems, and specific regulatory knowledge.

Full episode transcript

Host: Welcome back. Today we're going to be looking at some of the categories of medical devices and medical device manufacturers as well as some of the regulatory bodies that govern these devices and go through the submission approval process. Here today with Christian Espinosa, the founder and CEO of Blue Goat Cyber. Guest: Awesome. How you doing today Trevor? Host: Doing pretty well. How are you doing? Guest: You know, I've my head has my these two fingers have been kind of numb. I went shooting for like an hour and a half the day. I don't know if it's from shooting handguns so long or what but it's making typing very challenging for me. You ever had that problem from shooting? Host: Yeah, yeah, I, no, I get that problem once in a while. I mean, normally, I shoot kind of the racing guns, the 22 caliber, so I don't get too much, but, uh, whenever I go out for the bigger calipers or go out on big rifles, I kind of get that same issue. Guest: Okay. I thought maybe something was happening to my hands here. Yeah, I'm looking forward to our episode today. We're going to talk about some important topics with, uh, the regulatory landscape. Regulatory affairs can be kind of boring, so hopefully we can cover this in a non boring manner. And, uh, one of the things with medical device manufacturers, I feel they fall into two main categories, at least the clients that deal with us, there's two main categories. There's the startups and then there's the large companies. It seems like we rarely get somebody in the middle. I mean, maybe a few, but it's mainly the startups and large companies. And a lot of the startups are VC or venture capital funded. And what happens is they kind of forget about cybersecurity until the very end and the whoever their regulatory affairs person is says hey, we got to do the cybersecurity stuff. And the product has already been developed. So then they contact us and at this point we have to like retroactively fix a bunch of things or bolt on some security which isn't the ideal way to do this. And this happens with large companies too. Um, what do you think the ideal way to handle the security of this Trevor? Should it be like they they they start reading the FDA guidance and all of a sudden they realize when they're about to like submit their packet to the FDA that they forgot about it? Or should they do it like way earlier in the process? Host: In a perfect world, as soon as they have the idea for the device they should be accounting for security. Now like you said that's rarely actually the case but in an ideal situation you're able to account for security early and often. Pretty much any aspect of a device can be compromised in some way or another. Bad guys are unfortunately pretty crafty. So it can be easy for devices where security is an afterthought to get compromised in hundreds of different ways. That's why it's something that should be addressed at the very beginning. Um, now like you said that doesn't always happen. So's part of striking the balance is figuring out how can you address security once it's we're already down to the right side of the development process. I can't count how many times we have, you know, a potential client come to us and say, Hey, we need security considerations done for this medical device. We say, Great, when are you planning to submit? And they say, Oh, about three weeks from now. Go, Whoa, that's, that's a tight timeline. And, you know, that takes in all the documentation, penetration, testing, remediation, re-testing. It is not typically a three-week process. Guest: We can turn our part around the initial round of testing typically in three weeks, but it's gonna take them quite a while to fix all the stuff we identify, right? Host: Oh yeah, yeah, the initial round of testing. I mean, depending on how many hands you throw on the project, you can get through that pretty quickly but I guess it's a matter of how, how much you find from testing typically to see how long remediation cycle is. We have a lot of times where you don't find too much on testing. You give someone almost clean bill of health, they make a couple of tweaks and then they have a finished product the next day. Other times you absolutely eat them alive, you find you know, dozens of critical findings just tear apart a device and then, you know, suddenly, it's a Guest: doesn't sound very pleasant. Eat them alive and tear apart the device. Is that how you're describing the work?

1 / 7